Literature DB >> 29700120

Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.

Tomoya Hara1, Pham Tran Phuong1, Daiju Fukuda1,2, Koji Yamaguchi1, Chie Murata3, Sachiko Nishimoto1, Shusuke Yagi, Kenya Kusunose1, Hirotsugu Yamada1, Takeshi Soeki1, Tetsuzo Wakatsuki1, Issei Imoto3, Michio Shimabukuro2, Masataka Sata1.   

Abstract

BACKGROUND: The coagulation system is closely linked with vascular inflammation, although the underlying mechanisms are still obscure. Recent studies show that protease-activated receptor (PAR)-2, a major receptor of activated factor X, is expressed in both vascular cells and leukocytes, suggesting that PAR-2 may contribute to the pathogenesis of inflammatory diseases. Here we investigated the role of PAR-2 in vascular inflammation and atherogenesis.
METHODS: We generated apolipoprotein E-deficient ( ApoE-/-) mice lacking systemic PAR-2 expression ( PAR-2-/- ApoE-/-). ApoE-/- mice, which lack or express PAR-2 only in bone marrow (BM) cells, were also generated by BM transplantation. Atherosclerotic lesions were investigated after 20 weeks on a Western-type diet by histological analyses, quantitative reverse transcription polymerase chain reaction, and Western blotting. In vitro experiments using BM-derived macrophages were performed to confirm the proinflammatory roles of PAR-2. The association between plasma activated factor X level and the severity of coronary atherosclerosis was also examined in humans who underwent coronary intervention.
RESULTS: PAR-2-/- ApoE-/- mice showed reduced atherosclerotic lesions in the aortic arch ( P<0.05) along with features of stabilized atherosclerotic plaques, such as less lipid deposition ( P<0.05), collagen loss ( P<0.01), macrophage accumulation ( P<0.05), and inflammatory molecule expression ( P<0.05) compared with ApoE-/- mice. Systemic PAR2 deletion in ApoE-/-mice significantly decreased the expression of inflammatory molecules in the aorta. The results of BM transplantation experiments demonstrated that PAR-2 in hematopoietic cells contributed to atherogenesis in ApoE-/- mice. PAR-2 deletion did not alter metabolic parameters. In vitro experiments demonstrated that activated factor X or a specific peptide agonist of PAR-2 significantly increased the expression of inflammatory molecules and lipid uptake in BM-derived macrophages from wild-type mice compared with those from PAR-2-deficient mice. Activation of nuclear factor-κB signaling was involved in PAR-2-associated vascular inflammation and macrophage activation. In humans who underwent coronary intervention, plasma activated factor X level independently correlated with the severity of coronary atherosclerosis as determined by Gensini score ( P<0.05) and plaque volume ( P<0.01).
CONCLUSIONS: PAR-2 signaling activates macrophages and promotes vascular inflammation, increasing atherosclerosis in ApoE-/- mice. This signaling pathway may also participate in atherogenesis in humans.

Entities:  

Keywords:  atherosclerosis; inflammation; macrophage; protease-activated receptor-2

Mesh:

Substances:

Year:  2018        PMID: 29700120     DOI: 10.1161/CIRCULATIONAHA.118.033544

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

2.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Macrophage protease-activated receptor 2 regulates fetal liver erythropoiesis in mice.

Authors:  Mona Saffarzadeh; Kristin Grunz; T Son Nguyen; Young K Lee; Maki Kitano; Sven Danckwardt; Carina D S Rodrigues; Hartmut Weiler; Sabine Reyda; Wolfram Ruf
Journal:  Blood Adv       Date:  2020-11-24

4.  Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation Through Activating Pparα Pathway.

Authors:  Zeng Wang; Huairui Shi; Huan Zhao; Zhen Dong; Buchang Zhao; Xinyu Weng; Rongle Liu; Xiao Li; Kai Hu; Yunzeng Zou; Aijun Sun; Junbo Ge
Journal:  Curr Mol Med       Date:  2018       Impact factor: 2.222

5.  Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice.

Authors:  Jelle J Posthuma; Jens J N Posma; Rene van Oerle; Peter Leenders; Rick H van Gorp; Armand M G Jaminon; Nigel Mackman; Stefan Heitmeier; Leon J Schurgers; Hugo Ten Cate; Henri M H Spronk
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

6.  Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.

Authors:  Masato Narita; Kenji Hanada; Yosuke Kawamura; Hiroaki Ichikawa; Shuntaro Sakai; Yoshikazu Yokono; Maiko Senoo; Noritomo Narita; Michiko Shimada; Tomohiro Osanai; Ken Okumura; Hirofumi Tomita
Journal:  Hypertens Res       Date:  2021-07-20       Impact factor: 3.872

7.  Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.

Authors:  Nobuhiro Nakanishi; Koichi Kaikita; Masanobu Ishii; Yu Oimatsu; Tatsuro Mitsuse; Miwa Ito; Kenshi Yamanaga; Koichiro Fujisue; Hisanori Kanazawa; Daisuke Sueta; Seiji Takashio; Yuichiro Arima; Satoshi Araki; Taishi Nakamura; Kenji Sakamoto; Satoru Suzuki; Eiichiro Yamamoto; Hirofumi Soejima; Kenichi Tsujita
Journal:  Circ Rep       Date:  2020-03-04

8.  Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.

Authors:  Phuong Tran Pham; Daiju Fukuda; Shusuke Yagi; Kenya Kusunose; Hirotsugu Yamada; Takeshi Soeki; Michio Shimabukuro; Masataka Sata
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

Review 9.  Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection.

Authors:  Boghuma Titanji; Christina Gavegnano; Priscilla Hsue; Raymond Schinazi; Vincent C Marconi
Journal:  J Am Heart Assoc       Date:  2020-01-24       Impact factor: 5.501

10.  Upregulation of Protease-Activated Receptor 2 Promotes Proliferation and Migration of Human Vascular Smooth Muscle Cells (VSMCs).

Authors:  Mei Wei; Yongsheng Liu; Mingqi Zheng; Le Wang; Fangfang Ma; Yanchao Qi; Gang Liu
Journal:  Med Sci Monit       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.